Search

Your search keyword '"Imai, Masaki"' showing total 666 results

Search Constraints

Start Over You searched for: Author "Imai, Masaki" Remove constraint Author: "Imai, Masaki"
666 results on '"Imai, Masaki"'

Search Results

101. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters

106. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.

108. Observation of the Angular Momentum Compensation by Barnett Effect and NMR

110. Selection of antigenically advanced variants of seasonal influenza viruses

112. Characterization of H7N9 influenza A viruses isolated from humans

113. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury

114. Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

117. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate

118. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

119. Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution

120. Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

123. Plasticity of the Influenza Virus H5 HA Protein

125. Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model

126. Development of an mRNA vaccine against COVID-19

127. Chimeric hPIV2/Corona-Spike Nasal Vaccine Robustly Protects the Upper and Lower Airways Against SARS-CoV-2

128. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury

129. Comparison of Rapid Antigen Tests for COVID-19

138. Proenkephalin + regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function

139. Transmission of SARS-CoV-2 in Domestic Cats

141. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

143. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

144. Nature of Structural Instabilities in Superconducting Sr3Ir4Sn13

145. Antigenic variants of influenza B viruses isolated in Japan during the 2017‐2018 and 2018‐2019 influenza seasons

147. Expression of a Crry/p65 is reduced in acute lung injury induced by extracellular histones.

148. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens.

Catalog

Books, media, physical & digital resources